【摘要】 目的 :研究MDR1基因C3435T多态性与重症肌无力患者环孢素药物动力学的关系。方法 :采用荧光PCR的方法检测 96名重症肌无力 (MG)患者MDR1C3435T基因型 ,其中临床资料较全的 73名 ,对其环孢素用药的血药检测结果与基因型结果分析。结果 :重症肌无力患者MDR1C3435T的分布频率接近 1:1;野生型 3435CC患者的环孢素全血谷浓度高于杂合型和突变型 (P <0 .0 5 ) ,杂合型与突变型之间无明显差异。结论 :药物遗传学研究对环孢素治疗重症肌无力患者的临床合理用药有指导意义。更多还原

【Abstract】 AIM: To determine the effects of MDR1 C3435T on the pharmacokinetics of cyclosporine A in myasthenia gravis patients. METHODS: The genotype on MDR1 C3435T in 96 myasthenia gravis patients was detected using real time PCR method and 73 patients of them were studied further to determine the relationship of MDR1 C3435T polymorphism and trough blood concentrations of cyclosporine A. RESULTS: There were no difference between normal people and myasthenia gravis patients in MDR1 C3435T distribution. The average concentrations in patient of MDR1 3435CC was higher than that in patients of MDR1 3435CT and 3435TT. CONCLUSION: The pharmacogenomics is important to rationalize the medication of cyclosporine A.更多还原